Loading...
•
Sep 30, 2020
Cogent Biosciences Q3 2020 Earnings Report
Reported financial results for the third quarter ended September 30, 2020 and provided corporate updates.
Key Takeaways
Cogent Biosciences reported collaboration revenue of $0.3 million and a net loss of $50.0 million for the third quarter ended September 30, 2020. The company ended the quarter with $129.4 million in cash and cash equivalents.
Andrew Robbins was appointed President, CEO and Director.
Final results from PLX9486 + sunitinib Phase 1/2 study in GIST patients were selected for oral presentation at CTOS 2020 meeting.
The company completed Kiq LLC acquisition, gaining global rights to PLX9486.
Cogent Biosciences completed a $104.4M Series A preferred stock private placement.
Forward Guidance
This press release contains forward-looking statements regarding projected cash runways, future product development plans, upcoming results from clinical trials including from its lead program, PLX9486, and any future payouts under the CVR.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...